GlassScriptPhysician profile
Jeffrey C Tatar
NPI 1245401348
$3,767.13
in general payments reported to CMS, 2019-2025
12 companies · $936 in 2025
The $936 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.01 · 2022: $195 · 2023: $264 · 2024: $2,361 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088 · Consulting Fee: $1,063 · Education: $271 · Travel and Lodging: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,087.78 |
| Consulting Fee | $1,062.50 |
| Education | $270.99 |
| Travel and Lodging | $138.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,671.47 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $396.70 | 2022-2024 | Sotyktu |
| Ucb, INC. | $311.68 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $298.27 | 2024-2025 | Ebglyss, Taltz |
| Galderma Laboratories, L.P. | $250.59 | 2024-2025 | Nemluvio |
| Dermavant Sciences, INC. | $201.55 | 2023-2024 | Vtama |
| Amgen INC. | $157.63 | 2021-2025 | Tavneos, Otezla |
| Janssen Scientific Affairs, LLC | $146.47 | 2024 | Tremfya |
| Leo Pharma INC. | $100.00 | 2022 | |
| Organon LLC | $92.16 | 2025 | Vtama |
| Abbvie INC. | $80.50 | 2025 | |
| Genzyme Corporation | $60.11 | 2023-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Tatar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.